Cost-Effectiveness of Hypertension Treatment According to 2017 American College of Cardiology and American Heart Association Guidelines
Initiating hypertension treatment according to the ACC/AHA 2017 guideline in untreated US adults is cost-effective compared with JNC7 at 10 years. Prioritizing low-cost generic medicines and intensive BP treatment of high-CVD-risk adults with BP ≥140/90 mm Hg returns the most value.
Authors
- Ross Boylan
- Dhruv S. Kazi (ORCID: https://orcid.org/0000-0002-9510-2979)
- Pamela G. Coxson (ORCID: https://orcid.org/0000-0001-8254-2660)
- Andrew Edward Moran (ORCID: https://orcid.org/0000-0003-3554-0085)
- Brandon Kyle Bellows (ORCID: https://orcid.org/0000-0003-1395-6047)
- Kirsten Bibbins‐Domingo (ORCID: https://orcid.org/0000-0002-8962-0622)
- Lee M. Goldman
- Yiyi Zhang (ORCID: https://orcid.org/0000-0002-8663-5001)
- Joanne Penko
- Susan Hennessy (ORCID: https://orcid.org/0000-0002-6342-7138)
Institutions
- San Francisco General Hospital (US)
- Columbia University Irving Medical Center (US)
- University of California System (US)
- Deaconess Hospital (US)
- Columbia University (US)
Publication Details
- Journal
- Circulation Cardiovascular Quality and Outcomes
- Published
- 2025-08-01
- DOI
- https://doi.org/10.1161/circoutcomes.124.011872
- Citations
- 2
- Primary Topic
- Blood Pressure and Hypertension Studies
- Type
- article
- Field-Weighted Citation Impact
- 2.78